ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
주요 하이라이트
글리피칸3(GPC3)는 암 특이성이 높은 항원이며, 현재 암 표적 치료제 연구가 활발히 진행되고 있습니다. 항GPC3 단독요법은 간세포암(HCC)에서 제한적인 효과를 보였는데, 이는 치료 효과를 얻기 위해서는 높은 종양 포화도가 필요하기 때문인 것으로 추정됩니다. 이러한 한계는 CAR-T 세포와 TCR 변형 T 세포 요법을 포함한 2세대 전략에 대한 관심을 불러일으키고 있으며, 이를 통해 이러한 장벽을 극복할 수 있을 것으로 보입니다.
DelveInsight에 따르면, 항GPC3 치료에 기여하는 주요 적응증은 간세포암(HCC), 비소세포폐암(NSCLC), 위암, 기타 잠재적 GPC3 발현 종양 등입니다.
간세포암은 GPC3 표적 치료제 개발의 주요 관심사입니다. 간세포암의 주요 위험요인은 만성 알코올 사용, HBV 및 HCV 감염, 비만 및 당뇨병과 관련된 비알코올성 지방간염(NASH), 흔하지 않은 원인으로 원발성 담즙성 담관염, 혈색소 침착증, a1-항트립신 결핍증 등이 있습니다.
아스트라제네카는 지난 5월 ASCO 2025에서 GPC3 양성 진행성 또는 전이성 간세포암을 표적으로 하는 최초의 CD8 유도 T세포유도제(TCE) AZD9793을 평가한 RHEA-1 임상 1상 시험 데이터를 발표했습니다. 를 발표했습니다. 이를 통해 TCE 플랫폼 개발에서 아스트라제네카의 혁신성을 확인할 수 있습니다.
2025년 4월, 바이엘은 진행성 간세포암 환자의 GPC3 발현 종양을 치료하기 위해 설계된 표적 알파 방사성 의약품인 225Ac-GPC3(BAY 3547926)의 임상 1상 시험 개시를 발표했습니다.
비소세포폐암(NSCLC)도 GPC3 영역에서 주목받고 있습니다. 비소세포폐암은 전체 폐암의 약 85%를 차지하며, 소세포폐암(SCLC)보다 전이가 느린 반면 치사율은 여전히 높습니다. NSCLC는 선암, 편평상피암(남성에게 많고 흡연과 밀접한 관련이 있음), 대세포암, 덜 흔한 형태(선편평상피암, 육종 유사 암)로 분류됩니다. 항GPC3 치료제의 주요 개발업체로는 Eureka Therapeutics-ECT204(CAR-T), AstraZeneca-AZD9793(TCE), Bayer-225Ac-GPC3(방사성 의약품), CRISPR Therapeutics-RPCAR01(인공 세포치료제), BeOne Medicines-BGB-B(2033년)(비공개 양식) 등이 있습니다.
항 GPC3 요법의 미래는 유망합니다. 특히 임상 데이터가 성숙하고 GPC3 표적화 메커니즘이 더 잘 이해됨에 따라 이 클래스는 치료하기 어려운 암의 치료 환경을 바꿀 가능성이 높습니다.
항 GPC3 표적 치료제 시장 전망
세계 항GPC3 표적 치료 시장은 암 환자 증가, 임상 파이프라인 활동, 예상 규제 당국의 승인 등으로 인해 향후 몇 년 동안 성장할 것으로 예측됩니다.
Bayer, Carisma Therapeutics, Moderna, Eureka Therapeutics, AstraZeneca, CRISPR Therapeutics 등의 개발업체들은 각각 간세포암, 비소세포폐암 등의 치료제로 항GPC3 표적치료제 개발을 위해 개발하고 있습니다. 전반적으로, 이것은 큰 성장 잠재력을 가진 흥미진진한 새로운 클래스입니다. 향후 몇 년 동안 현재의 연구가 성숙해지면 항GPC3 표적치료제에 대한 이해가 깊어지고 암 치료에서 그 역할이 명확해질 것으로 보입니다.
본 보고서는 항GPC3 표적치료제의 주요 7개국(미국, 독일, 프랑스, 이탈리아, 스페인, 스페인, 영국, 일본) 시장을 조사 분석했으며, 각 지역 시장 규모와 예측, 현재 치료법, 신약, 미충족 수요 등의 정보를 전해드립니다.
목차
제1장 중요 지견
제2장 보고서 서론
제3장 항GPC3 표적 치료 주요 요약
제4장 주요 이벤트
제5장 항GPC3 표적 치료 역학 시장 예측 방법
제6장 주요 7개국의 항GPC3 표적 치료 시장 개요
시장 점유율 분포 : 치료법별(2025년)
시장 점유율 분포 : 치료법별(2040년)
시장 점유율 분포 : 적응증별(2025년)
시장 점유율 분포 : 적응증별(2040년)
제7장 항GPC3 표적 치료 : 배경과 개요
서론
다양한 적응증 항GPC3 표적 치료 가능성
항GPC3 표적 치료 임상 응용
제8장 항GPC3 표적 치료 표적 환자 집단
전제조건과 근거
주요 조사 결과
주요 7개 시장의 항GPC3 표적 치료 특정 적응증 총환자수
주요 7개 시장의 항GPC3 표적 치료 특정 적응증 총 적격 환자수
주요 7개 시장의 항GPC3 표적 치료 특정 적응증 총 치료 가능 환자수
제9장 항GPC3 표적 치료 등장
주요 경쟁
ECT204 : Eureka Therapeutics
AZD9793 : AstraZeneca
제10장 항GPC3 표적 치료 : 주요 7개 시장 분석
주요 조사 결과
항GPC3 표적 치료 시장 전망
항GPC3 표적 치료 결합 분석
항GPC3 표적 치료 주요 시장 예측의 전제조건
비용 상정과 리베이트
가격 동향
아날로그 평가
출시 연도와 치료 보급
주요 7개 시장의 항GPC3 표적 치료 전체 시장 규모 : 적응증별
미국
미국의 항GPC3 표적 치료 전체 시장 규모
미국의 항GPC3 표적 치료 시장 규모 : 적응증별
미국의 항GPC3 표적 치료 시장 규모 : 치료법별
유럽 4개국 및 영국
유럽 4개국 및 영국의 항GPC3 표적 치료 전체 시장 규모
유럽 4개국 및 영국의 항GPC3 표적 치료 시장 규모 : 적응증별
유럽 4개국 및 영국의 항GPC3 표적 치료 시장 규모 : 치료법별
일본
일본의 항GPC3 표적 치료 전체 시장 규모
일본의 항GPC3 표적 치료 시장 규모 : 적응증별
일본의 항GPC3 표적 치료 시장 규모 : 치료법별
제11장 SWOT 분석
제12장 KOL(Key Opinion Leader)의 견해
제13장 미충족 요구
제14장 시장 참여와 상환
제15장 부록
제16장 DelveInsight의 서비스 내용
제17장 면책사항
제18장 DelveInsight에 대해
LSH
영문 목차
영문목차
Key Highlights:
Glypican-3 (GPC3) is a highly cancer-specific antigen currently under active investigation for targeted cancer therapies. While anti-GPC3 monotherapy has shown limited efficacy in hepatocellular carcinoma (HCC), this is thought to be due to the need for high tumor saturation to achieve therapeutic benefit. This limitation has fueled interest in second-generation strategies, including CAR-T cells and TCR-engineered T cell therapies, which may overcome these barriers.
According to DelveInsight, key indications contributing to the Anti-GPC3 therapy landscape include: Hepatocellular carcinoma (HCC), Non-small cell lung cancer (NSCLC), Gastric cancer, and potentially other GPC3-expressing tumors.
HCC remains a leading focus in GPC3-targeted therapy development. Major risk factors for HCC include chronic alcohol use, HBV or HCV infections, obesity- or diabetes-related nonalcoholic steatohepatitis (NASH), less common causes: primary biliary cholangitis, haemochromatosis, and a1-antitrypsin deficiency.
In May 2025, AstraZeneca presented data at ASCO 2025 from the RHEA-1 first-in-human study evaluating AZD9793, a first-in-class CD8-guided T cell engager (TCE) targeting GPC3-positive advanced or metastatic HCC. This highlighted AstraZeneca's innovation in TCE platform development.
In April 2025, Bayer announced the initiation of a Phase I clinical trial for 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical designed to treat GPC3-expressing tumors in patients with advanced HCC.
Non-small cell lung cancer (NSCLC) is also gaining attention in the GPC3 space. NSCLC accounts for approximately 85% of all lung cancers, and although it metastasizes more slowly than small cell lung cancer (SCLC), it remains highly lethal. NSCLC is subtyped into adenocarcinomas, squamous cell carcinomas (more common in men and strongly associated with smoking), large cell carcinomas, and less common forms: adenosquamous and sarcomatoid carcinomas, leading developers of anti-GPC3 therapies include Eureka Therapeutics - ECT204 (CAR-T), AstraZeneca - AZD9793 (TCE), Bayer - 225Ac-GPC3 (radiopharmaceutical), CRISPR Therapeutics - RPCAR01 (engineered cell therapy), BeOne Medicines - BGB-B2033 (undisclosed modality).
The future of anti-GPC3 therapies looks promising. This class is well-positioned to transform the treatment landscape for hard-to-treat cancers, especially as clinical data matures and the mechanisms of GPC3-targeting become better understood.
DelveInsight's "Anti-GPC3 Targeted Therapies - Target Population, Competitive Landscape, and Market Forecast - 2040" report delivers an in-depth understanding of the Anti-GPC3 Targeted Therapies, historical and competitive landscape as well as its market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Anti-GPC3 Targeted Therapies market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Anti-GPC3 Targeted Therapies market size from 2020 to 2040. The report also covers current Anti-GPC3 Targeted Therapies treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Geography Covered:
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020-2040
Anti-GPC3 Targeted Therapies Understanding and Treatment Algorithm
GPC3 Overview
Glypican-3 (GPC3) is a well-established molecular target for hepatocellular carcinoma (HCC). As a member of the heparan sulfate proteoglycan family, GPC3 is anchored to the cell membrane and plays a crucial role in tumor biology. Clinically, GPC3 has been observed to be highly expressed in malignant liver cells while demonstrating little to no expression in normal hepatic tissues. This differential expression profile positions GPC3 as an ideal candidate for HCC-specific therapeutic interventions, enabling targeted drug delivery and reducing off-target effects in non-cancerous liver tissue.
Anti-GPC3 Targeted Therapies Market Overview
In recent years, there has been a growing interest in the exploration of Anti-GPC3 Targeted Therapies for targeting indications such as HCC and NSCLC.
Anti-GPC3 Targeted Therapies Epidemiology
The epidemiology chapter of Anti-GPC3 Targeted Therapies in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for Anti-GPC3 Targeted Therapies, total eligible patient pool in selected indications for Anti-GPC3 Targeted Therapies, and total treated cases in selected indications for Anti-GPC3 Targeted Therapies in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2040.
In the US, there were about 205,000 incident cases of NSCLC in 2024.
In 2024, localized HCC represented the highest number of cases among all HCC types across the 7MM.
In Japan, NSCLC affected more males than females, with approximately 69,000 cases in males and 53,000 in females.
Anti-GPC3 Targeted Therapies Drug Chapters
The drug chapter segment of the Anti-GPC3 Targeted Therapies report encloses a detailed analysis of clinical trial details of Anti-GPC3 Targeted Therapies, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Emerging Drugs
ECT204: Eureka Therapeutics
ECT204 is an investigational ARTEMIS T-cell therapy targeting GPC3, a promising HCC antigen found in more than 70% of HCC cells. ECT204 ARTEMIS T cells also incorporate Eureka's proprietary tumor infiltration technology demonstrating enhanced ability to infiltrate solid tumors in animal models, potentially leading to improved efficacy in patients.
ECT204 is currently being investigated in Eureka's ongoing ARYA-3 study, an open-label, dose-escalation, multi-center Phase I/II clinical trial in adult patients with GPC3-positive HCC. It has been granted Orphan drug designation (ODD) for the treatment of HCC.
AZD9793: AstraZeneca
AZD9793, a trispecific IgG1 monoclonal antibody, is a first-in-class CD8-targeted TCE that directly engages tumor-infiltrating T cells and GPC3+ tumors, forming a bridge that activates T cells leading to tumor cell lysis and T cell proliferation. AZD9793 promotes potent GPC3+ HCC cell killing through preferential engagement of CD8+ T cells while minimizing CD4+ T cell activation and unwanted cytokine release. The novel mechanism of action combines bivalent GPC3 binding, CD8-biased engagement, and low-affinity T cell receptor binding to improve cytotoxicity and reduce the risk of cytokine release syndrome compared with other TCEs.
225Ac-GPC3 (BAY 3547926): Bayer
225AC-GPC3 (BAY 3547926) is an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 (GPC3) in patients with advanced HCC. It is composed of a GPC3 targeting high-affinity antibody radiolabeled with actinium-225 (225Ac). 225Ac-GPC3 delivers highly potent alpha-particles to the GPC3-expressing cancer cells, with the potential to induce DNA double-strand breaks, reducing cancer cell viability which may potentially cause anti-tumor activity.
Anti-GPC3 Targeted Therapies Market Outlook
The global Anti-GPC3 Targeted Therapies market is expected to witness growth in the coming years, driven by the increasing incidences of cancer cases, clinical pipeline activity, and anticipated regulatory approvals.
Market players, including Bayer, Carisma Therapeutics, Moderna, Eureka Therapeutics, AstraZeneca, CRISPR Therapeutics, and others, are involved in developing drugs for Anti-GPC3 Targeted Therapies for the treatment of indications such as HCC, NSCLC, and others, respectively. Overall, this is an exciting new class with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of anti-GPC3 targeted Therapies and define their role in cancer therapies.
Anti-GPC3 Targeted Therapies Drugs Uptake
This section focuses on the uptake rate of potential approved and emerging Anti-GPC3 Targeted Therapies expected to be launched in the market during 2025-2040.
Anti-GPC3 Targeted Therapies Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.
The presence of numerous drugs under different stages is expected to generate immense opportunity for Anti-GPC3 Targeted Therapies market growth over the forecast period.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Anti-GPC3 Targeted Therapies.
KOL Views
To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on Anti-GPC3 Targeted Therapies evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.
DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Miyazaki, University of Pittsburgh Medical Center, Ochsner Lafayette General Medical Center, National Cancer Center, Memorial Sloan Kettering Cancer Center, and others.
Their opinion helps understand and validate current and emerging therapy treatment patterns or Anti-GPC3 Targeted Therapies market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.
In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Key Updates on Anti-GPC3 Targeted Therapies
In April 2025, BeOne Medicines presented preclinical data for BGB-B2033, a novel 4-1BB/GPC3 bispecific antibody at the AACR annual meeting.
In January 2025, CRISPR Therapeutics announced that they are advancing an autologous, gene-edited CAR T therapy targeting glypican-3 (GPC3) for the potential treatment of solid tumors and expect to initiate a clinical trial in the first half of 2025.
In November 2024, Carisma Therapeutics presented new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte therapy for the treatment of HCC, at SITC 2024.
The abstract list is not exhaustive, will be provided in the final report
Scope of the Report:
The report covers a segment of key events, an executive summary, and a descriptive overview of the Anti-GPC3 Targeted Therapies, explaining its mechanism, and therapies (current and emerging).
Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
A detailed review of the Anti-GPC3 Targeted Therapies market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM Anti-GPC3 Targeted Therapies market.
Anti-GPC3 Targeted Therapies Report Insights
Anti-GPC3 Targeted Therapies Targeted Patient Pool
Therapeutic Approaches
Anti-GPC3 Targeted Therapies Pipeline Analysis
Anti-GPC3 Targeted Therapies Market Size and Trends
Existing and Future Market Opportunities
Anti-GPC3 Targeted Therapies Report Key Strengths
16 years Forecast
The 7MM Coverage
Key Cross Competition
Drugs Uptake and Key Market Forecast Assumptions
Anti-GPC3 Targeted Therapies Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Qualitative Analysis (SWOT)
Key Questions:
What was the total market size of Anti-GPC3 Targeted Therapies, the market size by therapies, market share (%) distribution, and what would it look like in 2040? What are the contributing factors for this growth?
Which drug is going to be the largest contributor in 2040?
Which is the most lucrative market for Anti-GPC3 Targeted Therapies?
What are the pricing variations among different geographies for approved therapies?
How the reimbursement landscape has for Anti-GPC3 Targeted Therapies evolved since the first one was approved? Do patients have any access issues that are driven by reimbursement decisions?
What are the risks, burdens, and unmet needs of treatment with Anti-GPC3 Targeted Therapies? What will be the growth opportunities across the 7MM for the patient population of Anti-GPC3 Targeted Therapies?
What are the key factors hampering the growth of the market for Anti-GPC3 Targeted Therapies?
What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
What key designations have been granted to the therapies for Anti-GPC3 Targeted Therapies?
What is the cost burden of approved therapies on the patient?
Patient acceptability in terms of preferred therapy options as per real-world scenarios?
What are the country-specific accessibility issues of expensive, recently approved therapies?
Reasons to buy:
The report will help develop business strategies by understanding the latest trends and changing dynamics driving the Anti-GPC3 Targeted Therapies market.
Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Anti-GPC3 Targeted Therapies
4. Key Events
5. Epidemiology Market Forecast Methodology of Anti-GPC3 Targeted Therapies
6. Anti-GPC3 Targeted Therapies Market Overview at a Glance in the 7MM
6.1. Market Share (%) Distribution by Therapies in 2025
6.2. Market Share (%) Distribution by Therapies in 2040
6.3. Market Share (%) Distribution by Indications in 2025
6.4. Market Share (%) Distribution by Indications in 2040
7. Anti-GPC3 Targeted Therapies: Background and Overview
7.1. Introduction
7.2. Potential of Anti-GPC3 Targeted Therapies in Different Indications
7.3. Clinical Applications of Anti-GPC3 Targeted Therapies
8. Target Patient Pool of Anti-GPC3 Targeted Therapies
8.1. Assumptions and Rationale
8.2. Key Findings
8.3. Total Cases of Selected Indication for Anti-GPC3 Targeted Therapies in the 7MM
8.4. Total Eligible Patient Pool of Selected Indication for Anti-GPC3 Targeted Therapies in the 7MM
8.5. Total Treatable Cases in Selected Indication for Anti-GPC3 Targeted Therapies in the 7MM
9. Emerging Anti-GPC3 Targeted Therapies
9.1. Key Competitors
9.2. ECT204: Eureka Therapeutics
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
10.2.5. Analyst Views
9.3. AZD9793: AstraZeneca
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
10.3.5. Analyst Views
10. Anti-GPC3 Targeted Therapies: 7MM Analysis
10.1. Key Findings
10.2. Market Outlook of Anti-GPC3 Targeted Therapies
10.3. Conjoint Analysis of Anti-GPC3 Targeted Therapies
10.4. Key Market Forecast Assumptions of Anti-GPC3 Targeted Therapies
10.4.1. Cost Assumptions and Rebates
10.4.2. Pricing Trends
10.4.3. Analogue Assessment
10.4.4. Launch Year and Therapy Uptakes
10.5. Total Market Sizes of Anti-GPC3 Targeted Therapies by Indications in the 7MM
10.6. The United States
10.6.1. Total Market Size of Anti-GPC3 Targeted Therapies in the United States
10.6.2. Market Size of Anti-GPC3 Targeted Therapies by Indication in the United States
10.6.3. Market Size of Anti-GPC3 Targeted Therapies by Therapies in the United States
10.7. EU4 and the UK
10.7.1. Total Market Size of Anti-GPC3 Targeted Therapies in EU4 and the UK
10.7.2. Market Size of Anti-GPC3 Targeted Therapies by Indications in EU4 and the UK
10.7.3. Market Size of Anti-GPC3 Targeted Therapies by Therapies in EU4 and the UK
10.8. Japan
10.8.1. Total Market Size of Anti-GPC3 Targeted Therapies in Japan
10.8.2. Market Size of Anti-GPC3 Targeted Therapies by Indications in Japan
10.8.3. Market Size of Anti-GPC3 Targeted Therapies by Therapies in Japan
